

Prenatal Immunization Information Session for Healthcare Providers

- LAC DPH Updates:
 - Acetaminophen use in Pregnancy
 - Immunization updates
- Evidence-Based Strategies to Increase Prenatal Vaccine Uptake

Vaccine Preventable Disease Control Program

October 2, 2025



Update: Acetaminophen use in Pregnancy

Presented by: Priya Batra, MD, MS, FACOG





Beginning from the end – *take-home message*

Acetaminophen has long been established as a safe pain reliever and fever reducer for use during pregnancy.

The use of acetaminophen in pregnancy is appropriate when taken as needed, in moderation, and after consultation with a doctor.

American College of Obstetricians & Gynecologists (ACOG), 9/22/25

Why is this our message?

- Research to date
- Risks, benefits, and alternatives
- Positions from medical societies



Research to date



- Research on associations between autism and acetaminophen has been ongoing for two decades
- Collectively, this research has provided no definitive evidence of increased risk of autism associated with appropriate use of acetaminophen in pregnancy



Research to date



- Limitations of many studies: reliance on self-report, poor/no dosage information, variable neurodevelopmental outcomes, no controls for confounders
- Key reviews (for your reference)
 - Society for Maternal Fetal Medicine (SMFM) 2017
 - Food and Drug Administration (FDA) 2015
 - High quality individual studies (Gustavson et al., 2021 and Ahlqvist et al., 2024)



Risks, benefits, and alternatives



- Acetaminophen is an important tool in the management of fever and pain
 - Untreated fever: maternal hyperthermia in the first trimester is associated with increased risk of neural tube defects and other congenital anomalies
 - A first-line option for certain cases of pain (headache, postprocedure)
- Other analgesics may be used in pregnancy – consider restrictions, contraindications, and gestational age with your patients



Positions from medical societies



- Support statements from ACOG and SMFM
- Other organizations
 affirming the safety of
 appropriate
 acetaminophen use:
 <u>CA state health</u>
 <u>agencies</u>, <u>OB</u>
 <u>anesthesia</u>, <u>Canadian</u>
 OBGYN society





Update: Immunization

Presented by: Melanie Barr, MSN, CNS, RN







9/17/25 -Immunization standards for many CA laws changed from federal Advisory Committee on Immunization Practices (ACIP) to CDPH recommendations



Vaccines will be covered by health care insurers regulated by the <u>Department of Managed Health Care (PDF)</u>.



Liability protection for providers administering vaccines in accordance with CDPH guidance.



Pharmacists may administer vaccines recommended by CDPH to patients ≥3 years without a prescription



WCHA 2025-2026 Resp. Virus Season Immunization Recommendations

Age/Condition	COVID-19	Influenza	RSV			
Children	 All 6-23 months All 2-18 years with risk factors or never vaccinated against COVID-19 All who are in close contact with others with risk factors¹ All who choose protection¹ 	All 6 months and older	All younger than 8 months ² All 8-19 months with risk factors			
Pregnancy &	All who are planning pregnancy, pregnant, postpartum or lactating	All who are planning pregnancy, pregnant, postpartum or lactating	• 32-36 weeks gestational age ^{2,3}			
Adults	 All 65 years and older All younger than 65 years with risk factors All who are in close contact with others with risk factors All who choose protection 	• All	All 75 years and older ³ All 50-74 years with risk factors ³			

- 1. COVID-19 vaccine is available for persons 6 months and older.
- 2. Protect infants with either prenatal RSV vaccine or infant dose of nirsevimab or clesrovimab.
- 3. RSV vaccination during pregnancy or for adults is currently recommended once rather than annually.

Guest Presenter



Dr. Oluwatosin "Tosin" Goje, MD, MSCR Associate Professor of Obstetrics and Gynecology (OB/GYN) and Reproductive Biology at the Cleveland Clinic Lerner College of Medicine

Prenatal Immunization Session for Healthcare Providers

Tosin Goje, MD, MSCR, FACOG Associate Professor, Obstetrics &Gynecolog 10.2.25





Learning Objectives

01

Appraise the importance of immunization.

02

Demonstrate understanding of various reasons for vaccine hesitancy.

03

Apply evidencebased strategies to increase vaccine uptake.

Clinical Case 1

 22-year-old first-time mom in her second trimester, tells you she read online that the COVID-19 and flu vaccines can cause miscarriage. She tells you her mother and grandmother believe that vaccines during pregnancy are dangerous. She plans to avoid all shots during pregnancy.



Clinical Case 2


• 28-year-old first-time mom in her first trimester, tells you she read online that the flu vaccines can cause miscarriage. She tells you she gets the flu anytime she is vaccinated. She says she doesn't trust the vaccine and plans to avoid all shots during pregnancy.



Why Immunization Discussion is Important

- Vaccination is one of the most impactful health interventions, saving millions of lives globally every year.
- It is effective and efficient, safeguarding individuals from preventable diseases and contributing to the health and wellbeing of communities.
- Vaccination plays a pivotal role in driving economic progress by reducing healthcare cost and mitigating the burden of diseases.
- Maternal vaccination protects mother-baby dyad.

Vaccines Routinely Recommended During Pregnancy



Prenatal Care Checklist

Vaccines: ✓ Flu vaccine _____ declined ☐ RSV vaccine 32 0/7 - 36 6/7 (Sept - Feb) ☐ declined ☐ COVID vaccine ☐ declined ✓ TDaP 27-36 ☐ declined

ACOG's current recommendations for vaccination during pregnancy for Tdap, <u>COVID-19</u>, <u>influenza</u>, and <u>RSV</u> remain in place.

"For the sake of public health and the health of individuals across the country, immunization recommendations must be based on the full body of medical evidence, without bias or prejudice,"

"Immunization is especially important during pregnancy, when the risks of severe outcomes are heightened—and when vaccines can provide critical protection to the infant after birth. The prospect of unvaccinated patients and their infants developing respiratory distress and being hospitalized from COVID-19, flu, or RSV is frightening.

The fact remains that vaccination is our best tool to prevent serious outcomes from respiratory diseases."

Vaccines Routinely Recommended During Pregnancy

- Influenza vaccine
- Tdap vaccine
- COVID-19 vaccine
- RSV vaccine





Summary – Timing and administration of Maternal Vaccines

(ie. October through March) based on local RSV activity and other special circumstances


	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	June	July
Covid-19	Administe as availab	er as soon ole	However,	can be giver	at any time	of the year						
Flu		Ideally ad early fall (
Tdap	Can be administered at any time											
Maternal RSV Vaccine OR	Administer September through January in most of the Continental U.S. (2)											
Infant RSV Immunization nirsevimab			Ideally ad U.S. (2)	minister Oct	ober through	n March in m	nost of the co	ontinental				
	¹ Children who need 2 doses should receive their first dose as soon as possible (including during July and August). One dose of flu vaccine can be considered for pregnant people in their third trimester during July and August.											

² In jurisdictions with RSV seasonality that differs from most of the continental United States, including Alaska, southern Florida, Guam, Hawaii, Puerto Rico, U.S.-affiliated Pacific Islands, and U.S. Virgin Islands, providers should follow state, local, or territorial guidance. However, nirsevimab may be administered outside of routine seasonal administration

Know the Difference







Meeting the challenge of vaccine hesitancy

Determinants of Vaccine Hesitancy

Environmental Factors

Personal Factors

Social Factors

Safety and vaccine-related Factors

Environmental Factors

Socioeconomic Status

Access barriers

Complacency

Lack of information or misinformation

Vaccine mandates and Government policies



Personal Factors

Individual beliefs and preferences

Cultural and religious beliefs

Perception of disease risk

Trust in healthcare providers and institutions

Previous negative experiences

Historical trauma and discrimination

Social Factors

Social networks and peer influence

Media and information sources

Stigma and discrimination

Misinformation and disinformation

Addressing Hesitancy



Understand:

Understand the root cause



Align:

Align the intervention to the root cause



Adopt:

Adopt effective communications

Strategies to Improve Vaccine Confidence



EDUCATION AND CLEAR COMMUNICATION



COMMUNITY ENGAGEMENT



LEGISLATION AND POLICY



REDIRECT SOCIAL
MEDIA WITH
RELIABLE
INFORMATION



ADDRESS MISINFORMATION
AND DISINFORMATION



RESEARCH AND INNOVATION



Strategies during Pregnancy

01

Incorporate vaccine discussion into prenatal care

02

Have a checklist for vaccines in prenatal care

03

Include perinatal patients into clinical trials 04

Have a registry that is transparent and accessible to community

Strategies during Pregnancy

1

Acknowledge historical context

 Communities with mistrust of the healthcare system 2

Use trusted media and leaders to counteract misinformation

3

Listen to their voices and concerns

4

Outline strategies with community

Integrate Non-Medical Staff

- Doulas/Community Health Workers are allies in vaccine advocacy.
 - Trust, empathy, and education make a difference.
 - Close, ongoing contact with birthing individuals.
 - Deep cultural and emotional connection.
 - Unique position to influence health decisions.



The Obstetric Provider

- Counseling by an OB provider is powerful.
- Be clear and transparent.
 - Risks and Benefits.
 - Don't be dismissive.
- Continue to care for patients who decide not to be vaccinated, share resources, and encourage the continued use of prevention measures.
 - Document conversation: Accepted/Declined/Undecided

Summary – Timing and administration of Maternal Vaccines

(ie. October through March) based on local RSV activity and other special circumstances

Sep Dec Jan Feb Mar Oct Nov Apr May June July Aug Administer as soon However, can be given at any time of the year Covid-19 as available **Ideally administer** Flu early fall (1) Can be administered at any time Tdap Administer September through January in most of the Maternal RSV Continental U.S. (2) Vaccine Ideally administer October through March in most of the continental U.S. (2) Infant RSV **Immunization** 1 Children who need 2 doses should receive their first dose as soon as possible (including during July and August). One dose of flu vaccine can be considered for pregnant people nirsevimab in their third trimester during July and August. ² In jurisdictions with RSV seasonality that differs from most of the continental United States, including Alaska, southern Florida, Guam, Hawaii, Puerto Rico, U.S.-affiliated Pacific Islands, and U.S. Virgin Islands, providers should follow state, local, or territorial guidance. However, nirsevimab may be administered outside of routine seasonal administration

Tdap Vaccine

- Vaccinate between 27-36 weeks of gestation.
- Morbidity and mortality attributable to pertussis (whooping cough) occurs in infants who are 3 months and younger.
 Infants do not begin their own vaccine series against pertussis until approximately 2 months of age.
- Pregnant women should be counseled that the administration of Tdap during each pregnancy is safe and important to make sure that each newborn receives the highest possible protection against pertussis at birth.

COVID-19 Vaccine

- Vaccine may occur at anytime/trimester.
- ACOG strongly recommends in pregnancy.
 - Receive a vaccine or booster dose once available.
- COVID-19 infection in pregnancy has historically been associated with an increased risk of severe disease, adverse pregnancy outcomes, maternal death.
- Severe COVID-19 infection associated with increased risk of preterm birth.

RESEARCH

The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis

Shu Qin Wei MD PhD, Marianne Bilodeau-Bertrand MSc, Shiliang Liu MB PhD, Nathalie Auger MD MSc

RESULTS: We included 42 studies involving 438548 people who were pregnant.

INTERPRETATION: COVID-19 may be associated with increased risks of preeclampsia, preterm birth and other adverse pregnancy outcomes.



COVID-19 Vaccine

- There is no evidence of adverse maternal/ fetal effects from vaccinating pregnant individuals with the COVID-19 vaccine.
- The effectiveness of COVID-19 vaccines is similar in pregnant and nonpregnant individuals of similar age for prevention of COVID-19 infection and hospitalizations.
- COVID-19 vaccines decrease the risk of severe COVID-19 disease
 - Even if a patient gets sick after being vaccinated, their chance of becoming severely ill is extremely low.
- Vaccination during pregnancy provides passive immunity to the infant, protecting them from COVID-19 in the first few months of life before they can be vaccinated.

ACOG strongly <u>recommends</u> that all pregnant and lactating people receive an updated COVID-19 vaccine/booster.



Influenza Vaccine

- Vaccination between Oct-May. Preferably in October.
- Vaccination may occur at any trimester.
- Vaccine decreases risk of severe disease; it will not prevent all infections but ameliorates severity.
- Immune changes in pregnancy may increase the risk of flu complications such as preterm birth.
- Vaccine protects mother and baby; especially when administered in the third trimester.
 - Passive immunity to fetus.
 - Babies do not receive vaccine until 6 months of age.

Maternal RSV Vaccine

- Infant hospitalization rate is highest among 0-6 months of age.
- Estimated 100-300 children less than 5 years of age die yearly.
- Maternal vaccination occurs between Sept-January.
- Vaccination occurs between 32-36w6d during the RSV season.
- Do not administer if delivery is planned <2 weeks.
- It is administered once and do not give if patient received in previous pregnancy.
 - Counsel and discuss the administration of monoclonal antibodies within 1 week of delivery and by 8 months of infant life if maternal RSV was not given.

Maternal RSV Vaccine

- Efficacy: Vaccine reduced the risk of severe Lower Respiratory Tract Infection (LRTI) in infants by 81.9% within 90 days and 69.4% within 180 days post delivery.
- Effectiveness: Significantly decreased RSV LRTI and hospitalization in the first 6 months of life and markedly documented decrease in the first 3 months of infants' life.
- Safety: Preterm birth documented in research: 5.7% vs.4.7 %; however, in the 2023-2024 season, PTB was 4.1% (expected range in population 3.1%-6.1%).
 - Slight increased risk of gestational hypertension, however not severe preeclampsia.
- Razzini 2025, Perez 2025, Gentile 2025, Williams 2025, Moro 2024, Desilva 2025, Fleming Dutra 2023, Jones 2023.

Drivers Associated with Vaccination

WHAT PEOPLE THINK **PRACTICAL ISSUES** AND FEEL Know where the vaccine is Confidence in vaccine benefits Previous uptake of adult vaccination Confidence in vaccine safety Ease of access · Perceived risk - self Preferred site Perceived risk - others Availabilty of on-site Seeing negative information VACCINATION **MOTIVATION** vaccination* Intention to get a Receives COVID-19 vaccine recommended **SOCIAL PROCESSES** vaccines Willingness to Influential others support vaccination recommend a COVID-19 vaccine* Vaccination norms Workplace norms* Decision and travel autonomy Trust in vaccine providers Self-confidence in answering questions*



Key Takeaways

Train healthcare providers to deliver culturally competent counseling

Include shared medical decision

Involve community leaders in the conversation

Data collection is important

Meeting the challenge of vaccine hesitancy

VACCINE HESITANCY

REFERENCES

- Pullis BC, Hekel BE, Pullis RM. Addressing vaccine hesitancy: a nursing perspective. J Community Health Nurs 2024; 41(2):138–144. doi:10.1080/07370016.2024.2312144
- World Health Organization. Report of the SAGE Working Group on Vaccine Hesitancy. Updated November 12, 2014. https://www.who. int/docs/default-source/immunization/sage/2014/october/sageworking-group-revised-report-vaccine-hesitancy.pdf. Accessed June 21, 2024.
- Yang C, Lapp L, Tebbutt SJ. Overcoming COVID-19 vaccine hesitancy hurdles. Lancet 2023; 402(10408):1129–1130. doi:10.1016/S0140-6736(23)01425-3
- Dinga JN, Kabakama S, Njimoh DL, Chia JE, Morhason-Bello I, Lumu I. Quantitative synthesis of factors associated with COVID-19 vaccine acceptance and vaccine hesitancy in 185 countries. Vaccines (Basel) 2023; 12(1):34. doi:10.3390/vaccines12010034
- Gianfredi V, Berti A, Stefanizzi P, et al. COVID-19 vaccine knowledge, attitude, acceptance and hesitancy among pregnancy and breastfeeding: systematic review of hospital-based studies. Vaccines (Basel) 2023; 11(11):1697. doi:10.3390/vaccines11111697
- Wilson RJ, Paterson P, Jarrett C, Larson HJ. Understanding factors influencing vaccination acceptance during pregnancy globally: a literature review. Vaccine 2015; 33(47):6420–6429. doi:10.1016/j.vaccine.2015.08.046
- Silver D, Kim Y, Piltch-Loeb R, Abramson D. One year later: what role did trust in public officials and the medical profession play in decisions to get a booster and to overcome vaccine hesitancy? Prev Med Rep 2024; 38:102525, doi:10.1016/j.pmedr.2024.102525
- African American Research Collaborative. American COVID-19 vaccine poll. https://covidvaccinepoll.com/app/aarc/covid-19-vaccine-messaging/W. Accessed June 21, 2024.
- Darden PM, Jacobson RM. Impact of a physician recommendation. Hum Vaccin Immunother 2014; 10(9):2632–2635. doi:10.4161/hv.29020
- Hildreth JEK, Alcendor DJ. Targeting COVID-19 vaccine hesitancy in minority populations in the US: implications for herd immunity. Vaccines (Basel) 2021; 9(5):489. doi:10.3390/vaccines9050489
- KFF. KFF COVID-19 vaccine monitor: what we've learned. https:// www.kff.org/coronavirus-covid-19/poll-finding/kff-covid-19-vaccine-monitor-what-weve-learned-april-2021/. Accessed June 21, 2024.
- Wilkinson E, Jetty A, Petterson S, Jabbarpour Y, Westfall JM. Primary care's historic role in vaccination and potential role in COVID-19 immunization programs. Ann Fam Med 2021; 19(4):351–355. doi:10.1370/afm.2679
- Rodriguez RM, Torres JR, Chang AM, et al. The Rapid Evaluation of COVID-19 Vaccination in Emergency Departments for Underserved Patients study. Ann Emerg Med 2021; 78(4):502–510. doi:10.1016/j.annemergmed.2021.05.026
- Nuzhath T, Spiegelman A, Scobee J, Goidel K, Washburn D, Callaghan T. Primary care physicians' strategies for addressing COVID-19 vaccine hesitancy. Soc Sci Med 2023; 333:116150. doi:10.1016/j.socscimed.2023.116150
- Tuckerman J, Kaufman J, Danchin M. Effective approaches to combat vaccine hesitancy. Pediatr Infect Dis J 2022; 41(5):e243–e245. doi:10.1097/NR-0000000000003499
- Christakis NA, Fowler JH. Social contagion theory: examining dynamic social networks and human behavior. Stat Med 2013; 32(4):556-577. doi:10.1002/sim.5408
- Jansen VA, Stollenwerk N, Jensen HJ, Ramsay ME, Edmunds WJ, Rhodes CJ. Measles outbreaks in a population with declining vaccine uptake. Science 2003; 301(5634):804. doi:10.1126/science.1086726
- Fügenschuh M, Fu E. Overcoming vaccine hesitancy by multiplex social network targeting: an analysis of targeting algorithms and implications. Appl Netw Sci 2023; 8(1):67. doi:10.1007/s41109-023-00595-y.

- Berry CN, Walker K, Baker N, Trevor-Wright C. "I see a lot of crazy things and I don't know what to believe": lessons learned about health literacy and strategies for communicating with vaccinehesitant college students. Healthcare (Basel) 2023; 11(15):2212. doi:10.3390/healthcare11152212
- Dhallwal BK, Seth R, Thankachen B, et al. Leading from the frontlines: community-oriented approaches for strengthening vaccine delivery and acceptance. BMC Proc 2023; 17(suppl 7):5. doi:10.1186/s12919-023-00259-w
- Crosby LE, Real FJ, Cunnigham J, Mitchell M. Overcoming vaccine hesitancy using community-based efforts. Pediatr Clin North Am 2023; 70(2):359–370. doi:10.1016/j.pcl.2022.11.012
- Jalyeoba O, Villers M, Soper DE, Korte J, Salgado CD. Association between health care workers' knowledge of influenza vaccine and vaccine uptake. Am J Infect Control 2014; 42(1):69–70. doi:10.1016/j.ajic.2013.06.020
- Anraad C, van Empelen P, Ruiter RAC, et al. Promoting informed decision-making about maternal pertussis vaccination in centering pregnancy group-antenatal care: a feasibility study. Midwifery 2024; 128:103869. doi:10.1016/j.midw.2023.103869
- Santos HC, Goren A, Chabris CF, Meyer MN. Effect of targeted behavioral science messages on COVID-19 vaccination registration among employees of a large health system: a randomized trial. JAMA Netw Open 2021; 4(7):e2118702. doi:10.1001/jamanetworkopen.2021.18702
- Souza LD, Weinstein AC, Goje O. Factors influencing COVID-19 vaccination decision-making among pregnant and breastfeeding individuals (abstract 54). Am J Obstet Gynecol 2023; 228(2):5792. doi:10.1016/J.AJOG.2022.11.158
- Scharff DP, Mathews KJ, Jackson P, Hoffsuemmer J, Martin E, Edwards D. More than Tuskegee: understanding mistrust about research participation. J Health Care Poor Underserved 2010; 21(3):879–897. doi:10.1353/hpu.0.0323
- Flores LE, Frontera WR, Andrasik MP, et al. Assessment of the inclusion of racial/ethnic minority, female, and older individuals in vaccine clinical trials. JAMA Netw Open 2021; 4(2):e2037640. doi:10.1001/jamanetworkopen.2020.37640
- Wie SH, Jung J, Kim WJ. Effective vaccination and education strategies for emerging infectious diseases such as COVID-19. J Korean Med Sci 2023; 38(44):e371. doi:10.3346/jkms.2023.38.e371

Correspondence: Oluvratasin Goje, MD, MSCR, FACOG, Center for Specialized Wamen's Health, A10, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; gojeo@ccf.org



KEY FACTS ABOUT VAERS





Let's share some key facts about VAERS.



Questions?





Thank you!

For questions, please contact:

LACIPInfo@ph.lacounty.gov

